Details of the Drug

General Information of Drug (ID: DMRXW9P)

Drug Name
GSK-2130579A
Synonyms Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Drug Type
Vaccine
Cross-matching ID
TTD ID
D02JEW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Wilms tumor protein (WT1) TTZ8UT4 WT1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Wilms tumor protein (WT1) DTT WT1 5.12E-79 1.54 7.84
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01051063) Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy. U.S. National Institutes of Health.
2 Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012.